Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

Journal of clinical pharmacology - 1 Feb 2024

van der Heijden Lisa T, Ribbers Claire A, Vermunt Marit A C, Pluim Dick, Acda Manon, Tibben Matthijs, Rosing Hilde, Douma Joeri A J, Naipal Kishan, Bergman Andre M, Beijnen Jos H, Huitema Alwin D R, Opdam Frans L

Abstract excerpt

Patients with prostate cancer (PCa) have a lower docetaxel exposure for both intravenous (1.8-fold) and oral administration (2.4-fold) than patients with other solid cancers, which could influence efficacy and toxicity. An altered metabolism by cytochrome P450 3A (CYP3A) due to castration status might explain the observed difference in docetaxel pharmacokinetics. In this in vivo phenotyping, pharmacokinetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Docetaxel

Share to Midazolam

Share to Phenotype

Share to Prostatic Neoplasms

Source

Identifiers

PMID: 37789682
DOI: 10.1002/jcph.2362

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.PMID 37789682Read ↗

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.Semantic proximity Read ↗

Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphismsSemantic proximity Read ↗

Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.Semantic proximity Read ↗

Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients.Semantic proximity Read ↗

Pharmacogenetic pathway analysis of docetaxel elimination.Semantic proximity Read ↗

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.Semantic proximity Read ↗

Dexamethasone as a probe for docetaxel clearance.Semantic proximity Read ↗

Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.Semantic proximity Read ↗

Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.Semantic proximity Read ↗

Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir.Semantic proximity Read ↗

Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.Semantic proximity Read ↗

Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.